This Article Full Text (PDF) All Versions of this Article: 1074248408321461v1 13/3/183    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ferrer-García, J. C. Articles by Herrera-Ballester, A. Search for Related Content PubMed PubMed Citation Articles by Ferrer-García, J. C. Articles by Herrera-Ballester, A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ATORVASTATIN HEPTANOIC ACID PYRROLE Medline Plus Health Information Diabetes Social Bookmarking                         What's this?

Efficacy of Atorvastatin for Achieving Cholesterol Targets After LDL-Cholesterol Based Dose Selection in Patients With Type 2 Diabetes

Division of Diabetes, Consortium University General Hospital of Valencia, ferrer_juagar{at}gva.es

Eva Sanchez-Ballester, MD

Department of Internal Medicine, Consortium University General Hospital of Valencia, Valencia, Spain

Raquel Albalat-Galera

Division of Diabetes, Consortium University General Hospital of Valencia

Miguel Berzosa-Sanchez, MD

Department of Internal Medicine, Consortium University General Hospital of Valencia, Valencia, Spain

Agustín Herrera-Ballester, MD, PhD

Department of Internal Medicine, Consortium University General Hospital of Valencia, Valencia, Spain

We analyzed the feasibility of an intensive lipid-lowering strategy based on a starting dose of atorvastatin according to baseline and target low-density lipoprotein cholesterol (LDL-C) level (<2.6 mmol/L) in 202 statin-naïve patients with type 2 diabetes within 24 weeks. They were assigned to receive a daily dosage of atorvastatin based on their initial LDL-C levels. The primary endpoint was the proportion of patients achieving the LDL-C goal after 24 weeks of treatment. No changes were made in prescribed atorvastatin dosage. At the study end, 66.5% of the 188 patients completing the trial reached the LDL-C target (75%, 67%, 58% and 59% with 10, 20, 40 and 80 mg per day of atorvastatin, respectively) reached LDL-C target. Atorvastatin reduced the levels of total cholesterol, LDL-C, high density lipoprotein cholesterol (HDL-C) and tryglicerides by 29%, 35%, 3% and 22%, respectively, and all statin doses were well tolerated. Thus, individualizing the starting dose of atorvastatin according to baseline and target LDL-C levels, allowed a high proportion of type 2 diabetic patients to achieve the target within 24 weeks.

Key Words: atorvastatin • type 2 diabetes • dyslipidemia • low-density lipoprotein cholesterol

This version was published on September 1, 2008

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 13, No. 3, 183-188 (2008)
DOI: 10.1177/1074248408321461


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?